Fast Track, Breakthrough, and EUA: How the FDA Prioritizes Vaccine Approvals in Public Health Crises

Photo by Mufid Majnun on Unsplash

In early 2020, as a novel coronavirus swept across the globe, researchers raced against time to develop a vaccine. Traditional timelines that once spanned 10 years were condensed into mere months. While many feared cutting corners, the public witnessed an unprecedented regulatory sprint that still maintained scientific rigor. Behind the scenes, the U.S. Food and Drug Administration (FDA) deployed specialized pathways—Fast Track, Breakthrough Therapy, Accelerated Approval, and Emergency Use Authorization (EUA)—to bring safe, effective vaccines to market during a public health emergency.

These expedited mechanisms are not shortcuts; they are critical tools designed to address urgent medical needs. Understanding how these pathways differ and operate can demystify the vaccine approval process and clarify how scientific integrity is upheld even in times of crisis.

Fast Track: Speeding Up Communication and Review

Fast Track designation is granted to drugs and biologics that treat serious conditions and fill an unmet medical need. For vaccines, this typically applies when no preventative measure exists or when a new formulation offers significant advantages.

A Fast Track designation allows rolling review—where a company submits completed sections of its Biologics License Application (BLA) as they become available. This ongoing dialogue with the FDA accelerates feedback and helps resolve issues early.

According to the FDA’s own data, over 60% of Fast Track applications approved between 2018 and 2022 were for infectious disease treatments or preventatives, including several vaccines.

Breakthrough Therapy: Prioritizing Game-Changing Innovation

Breakthrough Therapy designation is reserved for products that show substantial improvement over existing therapies based on preliminary clinical evidence. This designation not only enables rolling reviews but also grants intensive guidance from senior FDA staff.

Pfizer-BioNTech’s COVID-19 vaccine received Breakthrough status, allowing close collaboration with regulators. This level of support is especially important for novel platforms, such as mRNA technology, which had not previously received FDA approval in vaccines.

The difference between Fast Track and Breakthrough often lies in the strength of early data. While both expedite review, Breakthrough products are seen as having the potential to dramatically shift clinical outcomes.

Accelerated Approval: Relying on Surrogate Endpoints

Accelerated Approval allows FDA to greenlight products based on surrogate endpoints that reasonably predict clinical benefit, rather than direct evidence of reduced illness or death. For example, a vaccine might gain approval based on antibody levels rather than actual infection reduction in trials.

This pathway is useful in high-risk scenarios where waiting for long-term results could delay response to deadly outbreaks. However, post-marketing confirmatory trials are required to validate the surrogate endpoints.

A 2023 report by Health Affairs noted that while accelerated approvals have helped advance oncology and rare disease drugs, their use in infectious disease remains limited—but may expand in future pandemics.

Emergency Use Authorization (EUA): A Crisis-Driven Mechanism

The most publicly visible pathway during COVID-19, EUA permits the use of unapproved medical products during emergencies when:

• The product may be effective in diagnosing, treating, or preventing serious or life-threatening diseases.
  
• The known and potential benefits outweigh the known and potential risks.
  
• No adequate, approved, and available alternatives exist.
  

EUA does not require as much data as a full BLA, but the FDA still evaluates clinical trial evidence, manufacturing controls, and safety monitoring plans. Public VRBPAC meetings are often held to enhance transparency.

The first COVID-19 vaccine EUA was granted to Pfizer-BioNTech in December 2020, less than a year after initial lab work. It represented the fastest development-to-authorization timeline in FDA history—without compromising rigorous review.

Real-World Impact and Perception

While these pathways offer speed, they have also drawn scrutiny. Some critics questioned whether EUA lowered the bar for safety. Yet extensive data collection continued post-authorization, and full FDA approval was contingent on submission of a comprehensive BLA.

A 2022 Pew Research Center study found that 75% of Americans believed the FDA acted appropriately during COVID-19’s vaccine rollout. However, confidence varied by demographic, underscoring the need for continued public education around the approval process.

Understanding vaccine development and approval, particularly in high-stakes scenarios, means recognizing how the FDA adapts to rapidly evolving threats while maintaining trust in science and governance.

The Role of Transparency and Oversight

Expedited pathways don’t function in isolation. Each comes with increased scrutiny, independent advisory reviews, and post-market safety monitoring like the Vaccine Adverse Event Reporting System (VAERS).

This multi-layered oversight ensures that accelerated timelines don’t translate into increased risk. It also helps build public trust, especially when data is made available through public hearings and peer-reviewed publications.

Conclusion: Speed, Science, and Safeguards

The FDA’s ability to accelerate vaccine approvals during public health crises is a testament to decades of regulatory evolution. These pathways represent a careful balance between urgency and caution, helping scientists and policymakers act swiftly without compromising safety.

As new pathogens emerge and global mobility increases, the demand for rapid vaccine deployment will grow. Are we prepared to support a system that moves fast and still protects public health?